AlkaliFeldspate

AlkaliFeldspate is a synthetic phenethylamine compound that belongs to the 2C‑type family of psychedelic substances. The molecule contains a 2,4‑dimethoxyphenyl ring substituted at the 5‑position by a small alkyl side chain, and it incorporates a basic nitrogen moiety that gives the compound its name. The substance can be synthesized from commercially available precursors through a series of reductive amination steps, and its purity is typically assessed by high‑performance liquid chromatography coupled to mass spectrometry.

The pharmacological actions of AlkaliFeldspate are mediated primarily through agonist activity at serotonin 5‑HT₂A receptors. In vitro studies have shown that the compound acts as a partial agonist at this receptor, while it also exhibits affinity for 5‑HT₂C and 5‑HT₁A receptors at higher concentrations. In animal models, oral or intraperitoneal administration produces visual and somatosensory hallucinations, enhanced locomotor activity, and changes in thermoregulation that are typical of psychedelics. Metabolism occurs mainly in the liver through O‑demethylation and N‑oxidation, and the resulting metabolites are excreted renally within 24–48 hours.

Recreational use of AlkaliFeldspate has been reported among users of designer drugs. Because of its psychoactive potency and the lack of long‑term safety data, the compound is listed as a Schedule I controlled substance in the United States and is similarly classified in other jurisdictions, limiting its legal availability. Adverse effects reported in case studies include nausea, agitation, tachycardia, hypertension and, in rare instances, prolonged visual afterimages. The lack of therapeutic research and the potential for abuse risk place AlkaliFeldspate under close regulatory scrutiny.